Bisantrene is both cardioprotective and anticancer. So far the evidence for its cardioprotective aspect is only from animals and cell culture studies, but it is clinically proven to significantly less cardiotoxic when used as a mono-agent. We are about to undertake a clinical study exploring the cardioprotective aspect later in 2024.
If you want to learn more I would recommend starting with the latest investor update from November 2023 [1]. The Triangle Insights report from April 2023 gives a very good overview of the market potential [2]. The real key to the value of bisantrene is it is both anticancer and cardioprotective (unique as far as I know) - this changes the entire economics of the drug thanks to the way drugs are paid for in the USA.
1. https://hotcopper.com.au/threads/ann-updated-strategy-and-investor-presentation.7713415/
2. https://hotcopper.com.au/threads/ann-race-releases-complete-cardio-protection-data-video.7330726/
Bisantrene is both cardioprotective and anticancer. So far the...
-
- There are more pages in this discussion • 390 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.72 |
Change
-0.120(6.52%) |
Mkt cap ! $308.2M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.89 | $1.71 | $288.9K | 162.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 883 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.76 | 2209 | 2 |
View Market Depth
| Last trade - 12.08pm 24/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |